Gilead Sciences in den Nachrichten
Entwicklung innovativer Gesundheitslösungen
Tamtam hat 20 aktuelle Artikel über Gilead Sciences gefunden.
- Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
- Gilead, PAHO agree on HIV prevention drug access in Latin America, Caribbean
- Gilead Partners With Pan American Health Organization on Lenacapavir Access for Latin America, Caribbean
- PAHO opens a new pathway to access lenacapavir for HIV prevention in Latin America and the Caribbean
- Should Gilead Sciences (GILD) Reconsider Its Global HIV Case After This PAHO Deal?
- Atlanta Black Pride Weekend celebrates 20 years, powered by Gilead Sciences
- Andrew Dickinson Sells 3,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock
- CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’
- Gilead Sciences Inc's Dividend Analysis
- Gilead Sciences Eyes HIV, Oncology Catalysts as Pipeline Enters Execution Mode
- Gilead Sciences Sees Sunlenca Launch Fueling Long-Term HIV Growth
- 'I've Said A Lot Of Thirsty Things At 2 A.M.' — Nicole Byer Says This One Question Belongs In Every Booty Call Conversation [Exclusive]
- Gilead Sciences at 12th Annual Cantor Fitzgerald Global Healthcare Conference: broader growth
- Gilead Opens State of the Art Research Center to Advance the Next Generation of Medicines
- Gilead opens new building on existing Foster City campus
- Gilead opens new research center at Foster City headquarters
- Gilead opens new research centre bringing together oncology, inflammation and research data science teams
- Gilead launches research facility in US for new medicine development
- How Bixlenvo Approval At Gilead Sciences (GILD) Has Changed Its Investment Story
- Assembly Bio converts HSV program from royalty deal to 40% US profit-share with Gilead
Von Tamtam gesammelte Artikel, die sich auf das Unternehmen beziehen, die neuesten zuerst. Jeder verlinkt auf seine Quelle.
Sie verkaufen an Unternehmen wie Gilead Sciences?
Tamtam findet die Unternehmen, die zu Ihrem idealen Kunden passen, recherchiert jeden Account und sagt Ihnen, wen Sie wann kontaktieren sollten.
Ähnliche Unternehmen finden